PYC Therapeutics (Australia) Insiders

PYC Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.3783) % which means that it has lost $0.3783 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6961) %, meaning that it generated substantial loss on money invested by shareholders. PYC Therapeutics' management efficiency ratios could be used to measure how well PYC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Total Current Liabilities is likely to gain to about 9.6 M in 2024. Liabilities And Stockholders Equity is likely to gain to about 95.8 M in 2024Common Stock Shares Outstanding is likely to drop to about 3.1 B in 2024. Net Loss is likely to gain to about (19.5 M) in 2024

PYC Therapeutics Workforce Comparison

The company has Profit Margin (PM) of (1.71) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.78) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.78.

PYC Therapeutics Benchmark Summation

PYC Therapeutics Notable Stakeholders

The success or failure of an entity such as PYC Therapeutics often depends on how effective the management is. PYC Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of PYC management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the PYC management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in PYC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PYC Therapeutics. Check PYC Therapeutics' Beneish M Score to see the likelihood of PYC Therapeutics' management manipulating its earnings.

When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.